The first EU Joint Clinical Assessment (JCA) is now published, marking a pivotal new milestone for both the pharmaceutical industry and Healthcare Authorities in Europe.
Looking at the first report (tovorafenib in pediatric low‑grade glioma), one thing is immediately clear: the JCA is not simply an assessment; it is a transparent map of the evidence landscape. It does not deliver a harmonized value verdict; instead, it shows where evidence is strong, where it is limited, and where it is absent.
In areas such as rare pediatric oncology, this is particularly evident. While eight PICOs were defined in collaboration with EU Member State HTA bodies, only one yielded a usable comparative result for inclusion in the JCA report, highlighting the structural challenges of generating comparative evidence across all decision-relevant scenarios.
At WEP, we believe that the future of clinical research will not be defined by technology alone, but by how effectively the industry combines innovation with human experience. This belief sits at the heart of how we support Sponsors in designing and delivering trials that perform under real-world conditions.
What is this First JCA Milestone Really Telling Us?
The PICO grid is the real market access map
- Payers assess value within specific clinical scenarios, defined by patient populations, comparators, outcomes, and levels of uncertainty, moving beyond broad regulatory indications.
- The JCA makes this fragmentation explicit, meaning what appears as a strong regulatory story can translate into multiple, differentiated access questions.
Early PICO anticipation and evidence planning are critical
- Generating relevant, methodologically robust evidence across PICOs must begin early in development. This is particularly challenging in rare diseases and targeted oncology, where trials are often small or single-arm with limited comparator data.
- In this case, a single indirect comparison, an unanchored Matching-Adjusted Indirect Comparison (MAIC), informed the narrative and was closely scrutinized due to small sample size, uncertainty, and methodological limitations.
- Proactive strategies such as thoughtful trial design, systematic literature reviews, and real-world evidence (RWE) generation are essential to address anticipated PICOs and avoid downstream access challenges.
The JCA sets the tone for national discussions
- While not binding, the JCA represents the first formal, EU-level view on comparative clinical evidence and associated uncertainty.
- It acts as a signal to national HTA bodies (e.g. G-BA, HAS, AIFA, AEMPS etc.), shaping subsequent reimbursement discussions.
- Where the JCA does not provide clear answers, national systems will interpret the evidence, potentially leading to access restrictions, pricing pressure, or additional evidence requirements.
What should health technology developers (HTDs) take away?
- Plan for the PICO grid early, not just the regulatory submission.
- Address evidence gaps proactively, not retrospectively.
- Build country-specific strategies and value narratives from the outset.
- Do not wait for JCA publication; by then, the evidence narrative is already set.
- Treat JCA as the starting point for national value defense, not the finish line.
Where WEP Clinical Can Support
At WEP Clinical, we see JCA as a fundamental shift in launch readiness and evidence strategy. WEP’s unique expertise in both the Early Access and Integrated Market Access Space enables us to support companies by:
- Anticipating the PICO landscape early
Helping map evidence against expected comparators and identify high-risk gaps ahead of submission - Strengthening evidence strategies
Supporting external control arms, integrated evidence planning, and fit-for-purpose comparative approaches where traditional trials are not feasible - Bridging evidence gaps pre- and post-approval
Designing early access programs with generation of RWE through data collection, strategically aligned with evolving HTA expectations - Supporting country-specific value defense
Translating JCA outputs into practical national pricing and access strategies, including unmet need positioning, and evidence commitments - Ensuring operational readiness
Supporting teams to navigate the pace and complexity of JCA requirements
Connect with the WEP Clinical Market Access team to discuss how early PICO planning, JCA readiness, and targeted evidence generation can strengthen your position for national HTA evaluations and support a more effective EU access strategy.
